Proscia Raises $50M to Advance AI-Driven Digital Pathology Platform

Digital pathology software company Proscia has announced a $50 million funding round led by Insight Partners, AI Capital Partners, and Triangle Peak Partners. This latest investment brings the company's total capital raised to $130 million and follows a year of record growth.

The funding will support three key strategic initiatives: accelerating the adoption of Proscia's digital pathology platform, integrating additional AI capabilities, and leveraging OEM partnerships with industry leaders like Agilent Technologies and Siemens Healthineers.

Proscia's flagship platform, Concentriq, is positioned as the only AI-driven pathology solution supporting the entire precision medicine value chain. The platform facilitates drug discovery, accelerates diagnostic processes, and connects life sciences organizations with laboratories to match patients with targeted treatments. According to the company, Concentriq now supports approximately 22,000 patient diagnoses daily.

A notable technology advancement within the platform is Concentriq Embeddings, which utilizes foundation models to accelerate AI development by 13 times the normal rate. This capability empowers researchers and data scientists to develop and deploy algorithms for critical applications including biomarker discovery, clinical trials, and companion diagnostics.

The company's precision medicine AI portfolio offers comprehensive applications designed to enhance diagnostic accuracy and efficiency. Proscia's solutions have gained regulatory approvals including FDA 510(k) clearance and CE-IVDR certification for its diagnostic software, establishing credibility across global markets.

"We are living through an extraordinary moment in medicine," said David West, Proscia's CEO. "Demand for advanced diagnostics is surging, digital pathology is gaining global traction, and AI is moving faster than the boldest predictions made just a few years ago. Patients are waiting to realize the future of precision medicine. With this investment, we will ensure that more pathologists and scientists can deliver it."

Proscia's growing customer base now includes 16 of the top 20 pharmaceutical companies worldwide, demonstrating the industry's confidence in the platform's capabilities to transform traditional pathology workflows into data-driven, AI-enhanced processes that can potentially improve both research outcomes and patient care.

The investment comes at a time when digital pathology and AI-driven diagnostic tools are increasingly viewed as essential components in advancing precision medicine initiatives, particularly in oncology and other complex disease areas where accurate, efficient pathological assessment is critical for treatment decisions.

Click here for the original news story.